Cannabis Dependence Clinical Trial
Official title:
Interactions Between Physical Activity and Cannabis Use in Adults
Verified date | June 2013 |
Source | Vanderbilt University |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
In this study the investigators will explore the relationship between physical activity and cannabis use. The investigators will compare regional brain activation detected by imaging technique(fRMI) before and after exercise in cannabis users and compare results with results from controls. The investigators hypothesize that the regional brain activation in response to visual cues (pictures related to cannabis use and food) will be different in cannabis users than in controls and that exercise will significantly alter brain responses to the cues.
Status | Completed |
Enrollment | 30 |
Est. completion date | June 2013 |
Est. primary completion date | January 2011 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years to 35 Years |
Eligibility |
Inclusion Criteria: - Cases and Controls must: - Be able to understand the study and provide written informed consent. - Be male or female 18 -35 years of age. - Be in generally good health - If female of childbearing potential, have a negative serum pregnancy test on study day Cases must: - Meet criteria for cannabis dependence as primary diagnosis as determined by the Substance Abuse module of SCID (Structured Clinical Interview for DSM-IV). - Not currently seeking treatment for cannabis dependence. - Have a positive urine drug test for cannabis on the study day - Avoid alcohol and other recreational drug use (except cannabis and/or nicotine) for 48 h before testing. Exclusion Criteria: - Cases and Controls must not: - Be pregnant or lactating - Have implanted electrical medical device (e.g. pacemaker, vagal nerve stimulator) - Have non-secure metallic foreign bodies - Have met criteria for another axis 1 diagnosis in the past 6 months - Receive psychotropically active or vasoactive medications (within 6 weeks of screen day) - Have chronic medical illness - Have epilepsy - Have a history of head injury that required hospitalization - Have claustrophobia - Have orthopedic or other problems precluding them from performing exercise protocol - Have body mass index (BMI) less than 19 kg/m2 - Weighing more than 275 pounds (MRI table limit) Cases must not: - Have current dependence, as determined by the SCID, on any psychoactive substance other than nicotine and/or cannabinoid - Have any serious medical or psychiatric illnesses and/or clinically significant symptoms, which in the judgment of the PI or his/her designee would make them unsafe, or would make compliance with the study protocol difficult or put the study staff at undue risk |
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Country | Name | City | State |
---|---|---|---|
United States | Vanderbilt University Medical Center | Nashville | Tennessee |
Lead Sponsor | Collaborator |
---|---|
Vanderbilt University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Craving for cannabis | 1 hour | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01005810 -
A Trial of N-Acetylcysteine (an Over-the-Counter Medicine) in Adolescents Who Smoke Marijuana
|
Phase 2 | |
Completed |
NCT00114439 -
Lithium Cannabis Withdrawal Study
|
Phase 2 | |
Completed |
NCT00350285 -
The Teen Marijuana Check-Up
|
Phase 2 | |
Completed |
NCT01618656 -
Safety and Efficacy of a FAAH-Inhibitor to Treat Cannabis Withdrawal
|
Phase 2 | |
Completed |
NCT01153490 -
Improving Substance Use and Clinical Outcomes in Heavy Cannabis Users With Quetiapine
|
Phase 4 | |
Completed |
NCT02946489 -
Facilitating the Behavioral Treatment of Cannabis Use Disorder
|
Phase 1 | |
Completed |
NCT02088177 -
Study of Long-Acting Injectable Naltrexone to Treat Cannabis Dependence
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT01565174 -
The Pharmaco-genetic and Brain Mechanisms Associated With Cannabis- Induced Psychosis
|
N/A | |
Completed |
NCT01697709 -
Quetiapine Pharmacotherapy for Cannabis Dependence
|
Phase 2 | |
Recruiting |
NCT04721353 -
Reducing Cannabis Overuse With Prazosin
|
Phase 4 | |
Completed |
NCT01603992 -
Quiting Marijuana Use: Self-report Study of Quitting Straegies and Withdrawal Symptoms
|
||
Completed |
NCT00167297 -
Atomoxetine for the Treatment of Cannabis Dependence
|
Phase 2 | |
Terminated |
NCT01598896 -
Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia
|
Phase 2/Phase 3 | |
Completed |
NCT01611948 -
Treatment for Cannabis Withdrawal and Dependence
|
Phase 2 | |
Recruiting |
NCT03221231 -
N-acetylcysteine for the Treatment of Cannabis Dependence: Working Mechanisms
|
Phase 4 | |
Not yet recruiting |
NCT03366909 -
Mindfulness Meditation and Cannabis Dependence : Therapy Effectiveness
|
N/A | |
Completed |
NCT01639872 -
Clozapine for Cannabis Use in Schizophrenia
|
Phase 4 | |
Not yet recruiting |
NCT06334016 -
Evaluating the Delivery and Effects of THC Vaping Liquids in the Bloodstream
|
Early Phase 1 | |
Completed |
NCT01793961 -
Effects of Chronic Intake of Cannabis on Contrast Sensitivity
|
N/A | |
Completed |
NCT01834794 -
Targeting Tobacco Cessation During Treatment for Cannabis Use Disorders
|
N/A |